Chiasma, Inc.
| Company Name | Chiasma, Inc. |
| Stock Symbol | CHMA |
| Status | 1 |
The Firm announces an investigation on behalf of investors of Chiasma, Inc. (“Chiasma” or the “Company”) (NASDAQ: CHMA) concerning the Company and its officers’ possible violations of federal securities laws. GPM is preparing a lawsuit on behalf of injured investors.
On April 15, 2016, Chiasma announced that it had received a Complete Response Letter from the United States Food and Drug Administration (“FDA”) rejecting the company’s New Drug Application for Mycapssa (octreotide) capsules for the maintenance treatment of U.S. adult patients with acromegaly. The Company later announced on April 18, 2016 that the FDA “did not believe the company’s application had provided substantial evidence of efficacy to warrant approval, and advised Chiasma that it would need to conduct another clinical trial in order to overcome this deficiency.”
On this news, Chiasma shares fell $6.42 per share, or 63%, to close at $3.75 per share on April 18, 2016, thereby injuring investors.
If you purchased Chiasma securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224 or by email to shareholders@glancylaw.com.
Submit Your Information
If you suffered a loss on your Chiasma, Inc. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.